According to Wind's data on May 8, 17 of 291 biomedical listed companies that have published their annual reports in 2018 have doubled their net profit over the same period of last year, mainly due to the prominent performance of their main businesses. Industry insiders pointed out that innovation is the foundation of the development of pharmaceutical enterprises. Future performance growth of biopharmaceutical companies will continue to revolve around innovation. It is a trend that the R&D expenditure of biomedical companies will only increase, and more and more enterprises will join the innovation team to create innovative genes with high recognition. According to the data, 33 of the above 291 biomedical companies have revenue of more than 10 billion yuan. Shanghai has the largest pharmaceutical revenue, amounting to 159.084 billion yuan. In terms of the growth rate of business revenue over the same period of last year, the four companies doubled their business revenue in 2018, namely Zhifei Biology, Guonong Science and Technology, Tianmu Pharmaceutical Industry and Baiyunshan. Their revenue increased by 289.43%, 164.69%, 103.23% and 101.55% respectively.
The net profit of 30 companies will exceed 1 billion yuan in 2018. Among them, 10 companies returned to their mothers with net profits exceeding 2 billion yuan. Hengrui Pharmaceutical has the largest net profit of 4.066 billion yuan. In terms of year-on-year growth, 17 companies have doubled their growth rates. The net profit of returning to the mother of North China Pharmaceutical Company increased 703.03% year on year, ranking first. The main business performance of biomedical companies which have achieved substantial growth in the above-mentioned performance is more prominent.
The main business performance of biomedical companies is more prominent. Taking North China Pharmaceutical as an example, during the reporting period, the company accelerated the industrial restructuring, highlighted the main pharmaceutical industry, focused on the development of chemical preparations, biological drugs, raw materials and other industries. The annual pharmaceutical revenue was 6.316 billion yuan, accounting for more than 69% of the total income, and the income in the field of biotechnology increased significantly over the same period of last year. Among them, the income of recombinant hepatitis B vaccine, amoxicillin sodium for injection, potassium clavulanate and cefotaxime sodium for injection exceeded 700 million yuan.
Huarong Securities Pharmaceutical Industry Analyst Zhang Keran told reporters that the promulgation of policies such as "opinions on deepening the reform of the examination and approval system to encourage innovation of pharmaceutical medical devices" and other policies, in line with the implementation of the in-depth medical reform, effectively improve the examination and approval system of pharmaceutical and medical devices, accelerate the pace of new drugs and advanced medical devices coming into the market, and speed up with foreign medical water. Flat rail. According to the annual report of biomedical companies in 2018, returning to the main business, consolidating the main business, strengthening the main business, keeping integrity and innovation are the foundation for the development of pharmaceutical enterprises, and also the core gene for the development and growth of enterprises. The future performance of biomedical companies will continue to revolve around innovation. Whether technological innovation or mode innovation will strengthen the barriers of enterprises and create a unique moat belonging to enterprises.
4+7 pilot urban purchasing policy has been steadily advancing. Under the background of encouraging innovation, it has become the industry consensus for biopharmaceutical companies to increase R&D investment. According to the data, in 2018, the R&D investment of 198 biomedical companies (excluding those that did not disclose R&D expenditure in 2017 or 2018) with comparable data of A shares totaled 34.598 billion yuan, compared with 25.175 billion yuan in 2017, an increase of 37.43% over the same period of last year. In 2018, 80 biomedical companies invested more than 100 million yuan in R&D. Hengrui Pharmaceutical's R&D investment is the most eye-catching, which is 2.67 billion yuan, and Fuxing Pharmaceutical's R&D investment is 2.507 billion yuan. According to the proportion of R&D investment in revenue, the top three biomedical companies are Beida Pharmaceutical, Guangshengtang Pharmaceutical and Puli Pharmaceutical, with R&D investment accounting for 48.2%, 28.32% and 23.47% respectively.
From the perspective of investment, innovative drugs, generic drugs and consistency evaluation become the key areas of delivery. Taking Hengrui Pharmaceutical as an example, during the reporting period, the company continued to increase R&D investment. In 2018, the total R&D investment was 2.67 billion yuan, an increase of 51.81% over the previous year. The R&D investment accounted for 15.33% of sales revenue, which strongly supported the R&D and innovation development of the company's projects. Last year, the company obtained two production batches of innovative pharmaceutical preparations, seven production batches of generic pharmaceutical preparations, 16 clinical batches of innovative drugs and two clinical batches of generic drugs.
From the research and development expenditure of biomedical companies published in 2018, Hengrui Pharmaceutical Company, Fuxing Pharmaceutical Company and Mingrui Medical Company are in the top three with R&D expenditure of 2.67 billion yuan, 2.50 billion yuan and 1.42 billion yuan respectively. This is also the current A-share bio-pharmaceutical industry R&D strength of the head enterprises. In the future, it is a trend that the R&D expenditure of pharmaceutical companies will only increase, and more and more enterprises will join the innovation team to create innovative genes with high recognition.
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
What kind of enterprises are to survive the reshuffle in the chemical industry
Exploratory Price Rise of Anthracite Local Mines
China's electricity and coal price index fell 5.26% in April from a year earlier
Ethylene glycol market will continue to decline weakly under negative pressure
Many factors may affect monoammonium or risk reduction
Coal prices fluctuate frequently with narrow fluctuations